Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825792 | Clinical Therapeutics | 2012 | 11 Pages |
Abstract
Drugs subject to restrictive coverage policies are substantially under-captured in administrative databases, leading to potential drug exposure misclassification in pharmacoepidemiologic studies relying on administrative databases. Pharmacoepidemiologic studies should clearly describe whether evaluated drugs are available as full benefits or subject to restrictive coverage policies and the potential impact on their results.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
John-Michael BSc (Pharm), MSc, Finlay A. MD, MSc, Jeffrey A. PhD, Dean T. PhD,